Skip to main content

Proposed Synergistic Effect of Calcium Channel Blockers with Lipid-Lowering Therapy in Retarding Progression of Coronary Atherosclerosis

Cardiovascular Drugs and Therapy volume 12, pages 111–118 (1998)Cite this article

Abstract

Lipid-lowering therapy now has undoubtedly proven to be an effective therapeutic modality to retard the progression of coronary atherosclerosis. An additional approach for prevention of the progression of atherosclerosis is calcium channel blocker (CCB) treatment. Evidence indicating that CCBs inhibit atherosclerosis is less unequivocal than the clear evidence for lipid-lowering therapy. Many investigations support the view that a number of key processes in atherosclerosis may be influenced by CCBs. From the “negative” and “positive” studies with CCBs performed in animals and humans we must conclude that apparently some, but not all, types or stages of the atherosclerotic process are inhibited by CCBs. To assess whether lipid-lowering therapy and CCB treatment may have an additive or synergistic beneficial effect on human atherosclerosis, which is conceivable because their anti-atherosclerotic properties differ, data from the angiographic lipid-lowering trial REGRESS (pravastatin vs. placebo) were reviewed. In REGRESS, patients in the pravastatin group had significantly less progression if cotreated with CCBs as compared with those with no CCB cotreatment, whereas in the placebo (no pravastatin) group no effect of CCB treatment was observed. With respect to angiographic new lesion formation, in the pravastatin group there were 50% less patients with new angiographic lesions if cotreated with CCBs as compared with no CCB cotreatment, whereas in the placebo (no pravastatin) group, again, no significant effect of CCB treatment was observed. No beneficial effects of CCB treatment on clinical events were observed during the 2-year study follow-up. In view of the correlation between angiographic progression and subsequent clinical events as demonstrated in several large trials, it is not unrealistic to also anticipate in this population, a beneficial effect on clinical events with longer follow-up. Although the REGRESS trial was not designed to evaluate combination therapy, the results suggest that addition of CCBs to HMG-CoA reductase inhibitor therapy (pravastatin) acts synergistically in retarding the progression of established coronary atherosclerosis. These results appear to warrant prospective randomized trials to determine in a more definitive manner the merits of this combination in the prevention of progression of coronary atherosclerosis. Currently a number of studies in these fields are being designed or are already underway.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Buchwald H, Matts JP, Fitch LL, et al. for the Program on the Surgical Control of the Hyperlipidemias (POSCH) Group. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA 1992;268:1429-1433.

    Google Scholar 

  2. Waters D, Craven TE, Lespérance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 1993;87:1067-1075.

    Google Scholar 

  3. Azen SP, Mack WJ, Cashin-Hemphill L, et al. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 1996;93:34-41.

    Google Scholar 

  4. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-3240.

    Google Scholar 

  5. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.

    Google Scholar 

  6. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet or diet plus cholestyramine in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-569.

    Google Scholar 

  7. Waters D, Higginson L, Gladstone P, et al. the CCAIT Study Group. Effect of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-968.

    Google Scholar 

  8. MAAS investigators. Effect of simvastatin on coronary atheroma: The multicentre anti-atheroma study (MAAS). Lancet 1994;344:633-638.

    Google Scholar 

  9. Jukema JW, Bruschke AVG, van Boven AJ, et al. on behalf of the REGRESS study group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The “Regression Growth Evaluation Statin Study” (REGRESS). Circulation 1995;91: 2528-2540.

    Google Scholar 

  10. Bestehorn H-P, Rensing UFE, Roskamm H, et al. The effect of simvastatin on progression of coronary artery disease. The Multicenter Coronary Intervention Study (CIS). Eur Heart J 1997;18:226-234.

    Google Scholar 

  11. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-162.

    Google Scholar 

  12. Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest 1981;68:1366-1369.

    Google Scholar 

  13. Strickberger SA, Russek LN, Phair RD. Evidence for increased aortic plasma membrane calcium transport caused by experimental atherosclerosis in rabbits. Circ Res 1988;62:75-80.

    Google Scholar 

  14. Kramsch DM, Aspen AJ, Rozler LJ. Atherosclerosis: Prevention by agents not affecting abnormal levels of blood lipids. Science 1981;213:1511-1512.

    Google Scholar 

  15. Loaldi A, Polese A, Montorsi P, et al. Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris. Am J Cardiol 1989;64:433-439.

    Google Scholar 

  16. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW, on behalf of the INTACT group investigators. Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet 1990;335:1109-1113.

    Google Scholar 

  17. Waters D, Lespérance J, Francetich M, et al. A controlled clinical trial to assess the effect of calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990;82:1940-53.

    Google Scholar 

  18. Waters D, Lespérance J. Calcium channel blockers and coronary atherosclerosis: From the rabbit to the real world. Am Heart J 1994;128:1309-1316.

    Google Scholar 

  19. Jukema JW, Zwinderman AH, van Boven AJ, Reiber JHC, van der Laarse A, Lie KI, Bruschke AVG. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. Arterioscler Thromb Vasc Biol 1996;16:425-430.

    Google Scholar 

  20. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-671.

    Google Scholar 

  21. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients hypercholesterolemia. Circulation 1994:89:2519-2524.

    Google Scholar 

  22. Lacoste L, Lam JYT, Hung J, Letchacovski, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-3177.

    Google Scholar 

  23. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-627.

    Google Scholar 

  24. Nayler WG. The antiatherogenic potential of the calcium antagonists, including amlodipine. In: Amlodipine. Berlin: Springer Verlag, 1993:178-198.

    Google Scholar 

  25. Mak T, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. Circ Res 1992;70:1099-1103.

    Google Scholar 

  26. Nilsson J, Sjolund M, Palmberg L, von Euler AM, Jonzon B, Thyberg J. The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation. Atherosclerosis 1985; 58:109-122.

    Google Scholar 

  27. Betz E, Weiss HK, Heinle H, Fotev Z. Calcium antagonists and atherosclerosis. J Cardiovasc Pharmacol 1991;18(Suppl. 10):S71-S75.

    Google Scholar 

  28. Block LH, Matthys H, Emmons LR, Perruchoud A, Erne P, Roth M. Ca2+ channel blockers modulate expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor genes stimulated by platelet-derived growth factor. Proc Natl Acad Sci USA 1991;88:9041-9045.

    Google Scholar 

  29. Nomomoto A, Mutoh S, Hagihara H, Yamaguchi I. Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist, nilvadipine. Atherosclerosis 1988;72:213-219.

    Google Scholar 

  30. McMurray HF, Chahwala SB. Amlodipine exerts a potent antimigrational effect on aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 1992;20(Suppl. A):S54-S56.

    Google Scholar 

  31. Ware JA, Johnston PC, Smith M, Salzman EW. Inhibition of human platelet aggregation and cytoplasmic calcium responses by calcium antagonists. Studies with aequorin and quin-2. Circ Res 1986;59:39-42.

    Google Scholar 

  32. Hernandez R, Carvajal AR, Armas-de Hernandez MJ, Guerrero-Pajuelo J, Armas-Padilla MC, Barragan O, Machado-de Alvarado I. The effects of the calcium antagonist amlodipine on blood pressure and platelet aggregation in hypertensive patients. Postgrad Med J 1991;67(Suppl. 5):S38-S40.

    Google Scholar 

  33. Heider JG, Weinstein DB, Pickens C, Lan S, Su CM. Antiatherogenic activity of the calcium channel blocker isradipine (PN200-110): A novel effect on matrix synthesis independent of calcium channel blockade. Transplant Proc 1987;19(Suppl. 5):96-101.

    Google Scholar 

  34. Chichester CO, Rodgers RL. Effect of doxazosin on vascular collagen synthesis, arterial pressure and serum lipids in the spontaneously hypertensive rat. J Cardiovasc Pharmacol 1987;10(Suppl.):S21-S26.

    Google Scholar 

  35. Catapano AL. Calcium antagonists and atherosclerosis. Experimental evidence. Eur Heart J 1997(Suppl. A):A80-A86.

    Google Scholar 

  36. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of incident myocardial infarction associated with anti-hypertensive drug therapies. JAMA 1995;274:620-625.

    Google Scholar 

  37. Lenfant C. The calcium channel blocker scare. Lessons for the future. Circulation 1995;91855-2856.

  38. HINT research group. Early treatment of unstable angina in the coronary care unit: A randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients with nifedipine or metoprolol or both. Br Heart J 1986;56:400-413.

    Google Scholar 

  39. The Israeli Sprint Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988;9:354-364.

    Google Scholar 

  40. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-392.

    Google Scholar 

  41. Gibson RS, Boden WE, Theroux P, et al. and the Diltiazem Reinfarction Group. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. N Engl J Med 1986;315:423-429.

    Google Scholar 

  42. Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs. verapamil in patients with stable angina pectoris. The Angina Prognosis Study In Stockholm (APSIS). Eur Heart J 1996;17:76-81.

    Google Scholar 

  43. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-1114.

    Google Scholar 

  44. Etingin OR, Hajjar DP. Calcium channel blockers enhance cholesteryl ester hydrolysis and decrease total accumulation in human aortic tissue. Circ Res 1990;66:185-190.

    Google Scholar 

  45. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994;344:793-795.

    Google Scholar 

  46. Mak IT, Weglicki WB. Comparative antioxidant activities of propanolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res 1990;66: 1449-1452.

    Google Scholar 

Download references

Author information

Affiliations

  1. Department of Cardiology, Leiden University Medical Center, Leiden

    J. Wouter Jukema, Arnoud Van der Laarse & Albert V.G. Bruschke

  2. Department of Cardiology, University Hospital, Groningen

    Ad J. van Boven

  3. Department of Medical Statistics, Leiden University, Leiden, The Netherlands

    Aeilko H. Zwinderman

Authors
  1. J. Wouter Jukema
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ad J. van Boven
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aeilko H. Zwinderman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arnoud Van der Laarse
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Albert V.G. Bruschke
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Jukema, J.W., van Boven, A.J., Zwinderman, A.H. et al. Proposed Synergistic Effect of Calcium Channel Blockers with Lipid-Lowering Therapy in Retarding Progression of Coronary Atherosclerosis. Cardiovasc Drugs Ther 12, 111–118 (1998). https://doi.org/10.1023/A:1007733311487

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007733311487

  • calcium channel blockers
  • pravastatin
  • atherosclerosis
  • lipids